Portfolio, Program, and Project Management in the Pharmaceutical and Biotechnology Industries

Edited by

Pete Harpum

WILEY
A John Wiley & Sons, Inc., Publication
## Contents

Preface ix  
Acknowledgments xi  
About the Authors xiii  

### Part One The Life Science Industry Context for Portfolio, Program, and Project Management

1. A Review of Project Management in Life Science Industry Sectors 3  
   **Thomas R. Dunson**

2. The Impact of Organizational Size on Drug Project Management 21  
   **Eric Morfin**

3. Drug Development in Biotechnology and How We Can Do It Better 33  
   **Susan Linna**

### Part Two The Portfolio, Program, and Project Management Approaches and Processes

   **Pete Harpum**

5. Portfolio Management in the Pharmaceutical Industry: Balancing Corporate Need with the Reality of Delivering Products to the Market 59  
   **John Bennett**
6. Program Management in Drug Development 85  
   Pauline Stewart-Long  
7. Project Control 101  
   Martin Powell  
8. Managing Uncertainty in Drug Projects 135  
   Pete Harpum and Thomas R. Dunson  
9. Managing Drug Safety Risk 155  
   Thomas R. Dunson and Eric Morfin  
10. Developing Program Strategy 175  
    Pete Harpum  
11. Developing Products with "Added Value" 197  
    Trevor J. Brown and Stephen Allport  

Part Three  Integrating the Processes  

    Martin D. Hynes III  
13. Integrated Drug Development: From Cradle to Grave and from Lab to Market 239  
    Stephen Allport and Terry Cooke-Davies  
14. The Development of P³M Capability in Drug Development Organizations 259  
    John Arrowsmith, Patrick Grogan, and Bob Moore  
    Pete Harpum, Ashley Jamieson, and Inge Fisher  

Bibliography 311  
Index 313